HIV reservoirs in vivo and new strategies for possible eradication of HIV from the reservoir sites

HIV/AIDS - Research and Palliative Care

Volumn 2, Issue , 2010, Pages 103-122

  Saksena, Nitin K ^a   Wang, Bin ^a   Zhou, Li ^a   Soedjono, Maly ^a   Shwen Ho, Yung ^a   Conceicao, Viviane ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

AIDS; Compartmentalization; Elimination strategies for reservoirs; HAART; HIV; Reservoirs

Indexed keywords

EID: 77954546854     PISSN: None     EISSN: 11791373     Source Type: Journal    
DOI: 10.2147/hiv.s6882     Document Type: Article

References (207)

1. Barre-Sinoussi F, Chermann JC, Rey F, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science. 1983;220:868-871.
2. UNAIDS. 2008 Report on the global AIDS epidemic. 2008. Available from: http://www.unaids.org/en/KnowledgeCentre/HIVData/Global-Report/2008/. Accessed May 10, 2010.
3. UNAIDS. 2007 AIDS epidemic update. Available from: http://www.unaids.org/en/KnowledgeCentre/HIVData/EpiUpdate/EpiUpdAr-chive/2007/default.asp. Accessed May 10, 2010.
4. Hirschel B, Opravil M. The year in review: antiretroviral treatment. Aids. 1999;13 Suppl A:S177-S187.
5. Wong JK, Hezareh M, Gunthard HF, et al. Recovery of replication-com- petent HIV despite prolonged suppression of plasma viremia. Science. 1997;278:1291-1295.
6. Blankson JN, Persaud D, Siliciano RF. The challenge of viral reservoirs in HIV-1 infection. Annu Rev Med. 2002;53:557-593.
7. Worgall S, Connor R, Kaner RJ, et al. Expression and use of human immunodeficiency virus type 1 coreceptors by human alveolar macrophages. J Virol. 1999;73:5865-5874.
8. Potter SJ, Dwyer DE, Saksena NK. Differential cellular distribution of HIV-1 drug resistance in vivo: evidence for infection of CD8+ T cells during HAART. Virology. 2003;305:339-352.
9. Chun TW, Finzi D, Margolick J, Chadwick K, Schwartz D, Siliciano RF. In vivo fate of HIV-1-infected T cells: quantitative analysis of the transi- tion to stable latency. Nat Med. 1995;1:1284-1290.
10. Clarke JR, Taylor IK, Fleming J, Nukuna A, Williamson JD, Mitchell DM. The epidemiology of HIV-1 infection of the lung in AIDS patients. Aids. 1993;7:555-560.
11. Di Stefano M, Sabri F, Leitner T, et al. Reverse transcriptase sequence of paired isolates of cerebrospinal fluid and blood from patients infected with human immunodeficiency virus type 1 during zidovudine treatment. J Clin Microbiol. 1995;33:352-355.
12. Poss M, Martin HL, Kreiss JK, et al. Diversity in virus populations from genital secretions and peripheral blood from women recently infected with human immunodeficiency virus type 1. J Virol. 1995;69:8118-8122.
13. Chun TW, Carruth L, Finzi D, et al. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature. 1997;387:183-188.
14. Delwart EL, Mullins JI, Gupta P, et al. Human immunodeficiency virus type 1 populations in blood and semen. J Virol. 1998;72:617-623.
15. van't Wout AB, Ran LJ, Kuiken CL, Kootstra NA, Pals ST, Schuitemaker H. Analysis of the temporal relationship between human immunodeficiency virus type 1 quasispecies in sequential blood samples and various organs obtained at autopsy. J Virol. 1998;72:488-496.
16. Saksena NK, Potter SJ. Reservoirs of HIV-1 in vivo: implications for antiretroviral therapy. AIDS Rev. 2003;5:3-18.
17. Tenner-Racz K, Racz P, Schmidt H, et al. Immunohistochemical, electron microscopic and in situ hybridization evidence for the involvement of lymphatics in the spread of HIV-1. Aids. 1988;2: 299-309.
18. Pantaleo G, Graziosi C, Butini L, et al. Lymphoid organs function as major reservoirs for human immunodeficiency virus. Proc Natl Acad Sci U S A. 1991;88:9838-9842.
19. Fox CH, Tenner-Racz K, Racz P, Firpo A, Pizzo PA, Fauci AS. Lymphoid germinal centers are reservoirs of human immunodeficiency virus type 1 RNA. J Infect Dis. 1991;164:1051-1057.
20. Haase AT, Henry K, Zupancic M, et al. Quantitative image analysis of HIV-1 infection in lymphoid tissue. Science. 1996;274:985-989.
21. Cavert W, Notermans DW, Staskus K, et al. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science. 1997;276:960-964.
22. Cheynier R, Henrichwark S, Hadida F, et al. HIV and T cell expansion in splenic white pulps is accompanied by infiltration of HIV-specific cytotoxic T lymphocytes. Cell. 1994;78:373-387.
23. Frost SD, Gunthard HF, Wong JK, Havlir D, Richman DD, Leigh Brown AJ. Evidence for positive selection driving the evolution of HIV-1 env under potent antiviral therapy. Virology. 2001;284:250-258.
24. Wong JK, Gunthard HF, Havlir DV, et al. Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure. Proc Natl Acad Sci U S A. 1997;94:12574-12579.
25. Lafeuillade A, Poggi C, Tamalet C, Profizi N. Human immunodeficiency virus type 1 dynamics in different lymphoid tissue compartments. J Infect Dis. 1997;176:804-806.
26. Tamalet C, Lafeuillade A, Fantini J, Poggi C, Yahi N. Quantification of HIV-1 viral load in lymphoid and blood cells: assessment during four-drug combination therapy. AIDS. 1997;11:895-901.
27. Gunthard HF, Wong JK, Ignacio CC, et al. Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy. J Virol. 1998;72:2422-2428.
28. Brandtzaeg P. Overview of the mucosal immune system. Curr Top Microbiol Immunol. 1989;146:13-25.
29. Poles MA, Elliott J, Taing P, Anton PA, Chen IS. A preponderance of CCR5(+) CXCR4(+) mononuclear cells enhances gastrointestinal mucosal susceptibility to human immunodeficiency virus type 1 infection. J Virol. 2001;75:8390-8399.
30. Clayton F, Snow G, Reka S, Kotler DP. Selective depletion of rectal lamina propria rather than lymphoid aggregate CD4 lymphocytes in HIV infection. Clin Exp Immunol. 1997;107:288-292.
31. Lim SG, Condez A, Lee CA, Johnson MA, Elia C, Poulter LW. Loss of mucosal CD4 lymphocytes is an early feature of HIV infection. Clin Exp Immunol. 1993;92:448-454.
32. Schneider T, Jahn HU, Schmidt W, Riecken EO, Zeitz M, Ullrich R. Loss of CD4 T lymphocytes in patients infected with human immunodeficiency virus type 1 is more pronounced in the duodenal mucosa than in the peripheral blood. Berlin Diarrhea/Wasting Syndrome Study Group. Gut. 1995;37:524-529.
33. Mellors JW, Rinaldo CRJr, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science. 1996;272:1167-1170.
34. Quinn TC. Viral load, circumcision and heterosexual transmission. Hopkins HIV Rep. 2000;12:1, 5, 11.
35. Fleming DT, Wasserheit JN. From epidemiological synergy to public health policy and practice: the contribution of other sexually transmitted diseases to sexual transmission of HIV infection. Sex Transm Infect. 1999;75:3-17.
36. Amerongen HM, Weltzin R, Farnet CM, Michetti P, Haseltine WA, Neutra MR. Transepithelial transport of HIV-1 by intestinal M cells: a mechanism for transmission of AIDS. J Acquir Immune Defic Syndr. 1991;4:760-765.
37. Fotopoulos G, Harari A, Michetti P, Trono D, Pantaleo G, Kraehenbuhl JP. Transepithelial transport of HIV-1 by M cells is receptor-mediated. Proc Natl Acad Sci U S A. 2002;99:9410-9414.
38. Frankel SS, Wenig BM, Burke AP, et al. Replication of HIV-1 in dendritic cell-derived syncytia at the mucosal surface of the adenoid. Science. 1996;272:115-117.
39. Meng G, Sellers MT, Mosteller-Barnum M, Rogers TS, Shaw GM, Smith PD. Lamina propria lymphocytes, not macrophages, express CCR5 and CXCR4 and are the likely target cell for human immunodeficiency virus type 1 in the intestinal mucosa. J Infect Dis. 2000;182:785-791.
40. Cerf-Bensussan N, Guy-Grand D. Intestinal intraepithelial lymphocytes. Gastroenterol Clin North Am. 1991;20:549-576.
41. Lee SH, Starkey PM, Gordon S. Quantitative analysis of total macrophage content in adult mouse tissues. Immunochemical studies with monoclonal antibody F4/80. J Exp Med. 1985;161:475-489.
42. Ullrich R, Schieferdecker HL, Ziegler K, Riecken EO, Zeitz M. gamma delta T cells in the human intestine express surface markers of activation and are preferentially located in the epithelium. Cell Immunol. 1990;128:619-627.
43. Schnittman SM, Lane HC, Greenhouse J, Justement JS, Baseler M, Fauci AS. Preferential infection of CD4+ memory T cells by human immunodeficiency virus type 1: evidence for a role in the selective T-cell functional defects observed in infected individuals. Proc Natl Acad Sci U S A. 1990;87:6058-6062.
44. Anton PA, Elliott J, Poles MA, et al. Enhanced levels of functional HIV-1 co-receptors on human mucosal T cells demonstrated using intestinal biopsy tissue. AIDS. 2000;14:1761-1765.
45. Smith PD, Meng G, Shaw GM, Li L. Infection of gastrointestinal tract macrophages by HIV-1. J Leukoc Biol. 1997;62:72-77.
46. Smith PD, Smythies LE, Mosteller-Barnum M, et al. Intestinal macro- phages lack CD14 and CD89 and consequently are down-regulated for LPS- and IgA-mediated activities. J Immunol. 2001;167:2651-2656.
47. Li S, Juarez J, Alali M, et al. Persistent CCR5 utilization and enhanced macrophage tropism by primary blood human immunodeficiency virus type 1 isolates from advanced stages of disease and comparison to tissue-derived isolates. J Virol. 1999;73:9741-9755.
48. Smith PD, Fox CH, Masur H, Winter HS, Alling DW. Quantitative analysis of mononuclear cells expressing human immunodeficiency virus type 1 RNA in esophageal mucosa. J Exp Med. 1994;1800:1541-1546.
49. Smith PD, Meng G, Sellers MT, Rogers TS, Shaw GM. Biological parameters of HIV-1 infection in primary intestinal lymphocytes and macrophages. J Leukoc Biol. 2000;68:360-365.
50. Resnick L, Berger JR, Shapshak P, Tourtellotte WW. Early penetration of the blood-brain-barrier by HIV. Neurology. 1988;38:9-14.
51. Nath A. Human immunodeficiency virus (HIV) proteins in neuropatho- genesis of HIV dementia. J Infect Dis. 2002;186 Suppl 2:S193-198.
52. Navia BA, Jordan BD, Price RW. The AIDS dementia complex: I. Clinical features. Ann Neurol. 1986;19:517-524.
53. Kure K, Weidenheim KM, Lyman WD, Dickson DW. Morphology and distribution of HIV-1 gp41-positive microglia in subacute AIDS encephalitis. Pattern of involvement resembling a multisystem degeneration. Acta Neuropathol. 1990;80:393-400.
54. Kaul M, Garden GA, Lipton SA. Pathways to neuronal injury and apoptosis in HIV-associated dementia. Nature. 2001;410:988-994.
55. Lawrence DM, Major EO. HIV-1 and the brain: connections between HIV-1-associated dementia, neuropathology and neuroimmunology. Microbes Infect. 2002;4:301-308.
56. Wang Z, Trillo-Pazos G, Kim SY, et al. Effects of human immunode ficiency virus type 1 on astrocyte gene expression and function: potential role in neuropathogenesis. J Neurovirol. 2004;10 Suppl 1:25-32.
57. Petito CK. Human immunodeficiency virus type 1 compartmentalization in the central nervous system. J Neurovirol. 2004;10 Suppl 1:21-24.
58. Gartner S. HIV infection and dementia. Science. 2000;287:602-604.
59. Liu Y, Tang XP, McArthur JC, Scott J, Gartner S. Analysis of human immunodeficiency virus type 1 gp160 sequences from a patient with HIV dementia: evidence for monocyte trafficking into brain. J Neurovirol. 2000;6 Suppl 1:S70-81.
60. Nottet HS, Gendelman HE. Unraveling the neuroimmune mechanisms for the HIV-1-associated cognitive/motor complex. Immunol Today. 1995;16:441-448.
61. Falangola MF, Petito CK. Choroid plexus infection in cerebral toxoplasmosis in AIDS patients. Neurology. 1993;43:2035-2040.
62. Falangola MF, Castro-Filho BG, Petito CK. Immune complex deposition in the choroid plexus of patients with acquired immunodeficiency syndrome. Ann Neurol. 1994;36:437-440.
63. Falangola MF, Hanly A, Galvao-Castro B, Petito CK. HIV infection of human choroid plexus: a possible mechanism of viral entry into the CNS. J Neuropathol Exp Neurol. 1995;54:497-503.
64. Hanly A, Petito CK. HLA-DR-positive dendritic cells of the normal human choroid plexus: a potential reservoir of HIV in the central nervous system. Hum Pathol. 1998;29:88-93.
65. Chen H, Wood C, Petito CK. Comparisons of HIV-1 viral sequences in brain, choroid plexus and spleen: potential role of choroid plexus in the pathogenesis of HIV encephalitis. J Neurovirol. 2000;6:498-506.
66. Petito CK, Chen H, Mastri AR, Torres-Munoz J, Roberts B, Wood C. HIV infection of choroid plexus in AIDS and asymptomatic HIV-infected patients suggests that the choroid plexus may be a reservoir of productive infection. J Neurovirol. 1999;5:670-677.
67. Overbaugh J, Anderson RJ, Ndinya-Achola JO, Kreiss JK. Distinct but related human immunodeficiency virus type 1 variant populations in genital secretions and blood. AIDS Res Hum Retroviruses. 1996;12:107-115.
68. Zhang H, Dornadula G, Beumont M, et al. Human immunodeficiency virus type 1 in the semen of men receiving highly active antiretroviral therapy. N Engl J Med. 1998;339:1803-1809.
69. Schlegel P CS. Physiology of male reproduction: the testes, epididymis, and ductus deferens. Campbell's Urology. 1998;7:1254-1286.
70. Coombs RW, Reichelderfer PS, Landay AL. Recent observations on HIV type-1 infection in the genital tract of men and women. AIDS. 2003;17:455-480.
71. Quayle AJ, Xu C, Mayer KH, Anderson DJ. T lymphocytes and macrophages, but not motile spermatozoa, are a significant source of human immunodeficiency virus in semen. J Infect Dis. 1997;176: 960-968.
72. Gupta P, Mellors J, Kingsley L, et al. High viral load in semen of human immunodeficiency virus type 1-infected men at all stages of disease and its reduction by therapy with protease and nonnucleoside reverse transcriptase inhibitors. J Virol. 1997;71:6271-6275.
73. Liuzzi G, Chirianni A, Clementi M, et al. Analysis of HIV-1 load in blood, semen and saliva: evidence for different viral compartments in a cross-sectional and longitudinal study. AIDS. 1996;10:F51-56.
74. da Silva M, Shevchuk MM, Cronin WJ, et al. Detection of HIV-related protein in testes and prostates of patients with AIDS. Am J Clin Pathol. 1990;93:196-201.
75. Pudney J, Anderson D. Orchitis and human immunodeficiency virus type 1 infected cells in reproductive tissues from men with the acquired immune deficiency syndrome. Am J Pathol. 1991;139: 149-160.
76. Nuovo GJ, Becker J, Simsir A, Margiotta M, Khalife G, Shevchuk M. HIV-1 nucleic acids localize to the spermatogonia and their progeny. A study by polymerase chain reaction in situ hybridization. Am J Pathol. 1994;144:1142-1148.
77. Muciaccia B, Filippini A, Ziparo E, Colelli F, Baroni CD, Stefanini M. Testicular germ cells of HIV-seropositive asymptomatic men are infected by the virus. J Reprod Immunol. 1998;41:81-93.
78. Shevchuk MM, Nuovo GJ, Khalife G. HIV in testis: quantitative histology and HIV localization in germ cells. J Reprod Immunol. 1998;41:69-79.
79. Howell AL, Edkins RD, Rier SE, et al. Human immunodeficiency virus type 1 infection of cells and tissues from the upper and lower human female reproductive tract. J Virol. 1997;71:3498-3506.
80. Belec L. The HIV-1 reservoir in the female genital tract. Afr Health. 1999;21:19-21.
81. Kovacs A, Wasserman SS, Burns D, et al. Determinants of HIV-1 shedding in the genital tract of women. Lancet. 2001;358:1593-1601.
82. Jeffrey AA, Israel-Biet D, Andrieu JM, Even P, Venet A. HIV isolation from pulmonary cells derived from bronchoalveolar lavage. Clin Exp Immunol. 1991;84:488-492.
83. Lewin SR, Kirihara J, Sonza S, Irving L, Mills J, Crowe SM. HIV-1 DNA and mRNA concentrations are similar in peripheral blood monocytes and alveolar macrophages in HIV-1-infected individuals. Aids. 1998;12:719-727.
84. Chayt KJ, Harper ME, Marselle LM, et al. Detection of HTLV-III RNA in lungs of patients with AIDS and pulmonary involvement. JAMA. 1986;256:2356-2359.
85. Twigg HL, Soliman DM, Day RB, et al. Lymphocytic alveolitis, bronchoalveolar lavage viral load, and outcome in human immuno- deficiency virus infection. Am J Respir Crit Care Med. 1999;159: 1439-1444.
86. White NC, Israel-Biet D, Coker RJ, Mitchell DM, Weber JN, Clarke JR. Different resistance mutations can be detected simultaneously in the blood and the lung oRf HIV-1 infected individuals on antiretroviral therapy. J Med Virol. 2004;72:352-357.
87. Bruggeman LA, Ross MD, Tanji N, et al. Renal epithelium is a previously unrecognized site of HIV-1 infection. J Am Soc Nephrol. 2000;11:2079-2087.
88. Marras D, Bruggeman LA, Gao F, et al. Replication and compartmen- talization of HIV-1 in kidney epithelium of patients with HIV-associated nephropathy. Nat Med. 2002;8:522-526.
89. Klatzmann D, Barre-Sinoussi F, Nugeyre MT, et al. Selective tropism of lymphadenopathy associated virus (LAV) for helper-inducer T lymphocytes. Science. 1984;225:59-63.
90. Ho DD, Rota TR, Hirsch MS. Infection of monocyte/macrophagesby human T lymphotropic virus type III. J Clin Invest. 1986;77: 1712-1715.
91. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science. 1996;272:872-877.
92. Kwa D, Vingerhoed J, Boeser-Nunnink B, Broersen S, Schuitemaker H. Cytopathic effects of non-syncytium-inducing and syncytium-inducing human immunodeficiency virus type 1 variants on different CD4(+) -T-cell subsets are determined only by coreceptor expression. J Virol. 2001;75:10455-10459.
93. Mo H, Monard S, Pollack H, et al. Expression patterns of the HIV type 1 coreceptors CCR5 and CXCR4 on CD4+ T cells and monocytes from cord and adult blood. AIDS Res Hum Retroviruses. 1998;14: 607-617.
94. Zack JA, Arrigo SJ, Chen IS. Control of expression and cell tropism of human immunodeficiency virus type 1. Adv Virus Res. 1990;38: 125-146.
95. Psallidopoulos MC, Schnittman SM, Thompson LM 3rd, et al. Integrated proviral human immunodeficiency virus type 1 is present in CD4+ peripheral blood lymphocytes in healthy seropositive individuals. J Virol. 1989;63:4626-4631.
96. Pantaleo G, Graziosi C, Demarest JF, et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature. 1993;362:355-358.
97. Hufert FT, van Lunzen J, Janossy G, et al. Germinal centre CD4+ T cells are an important site of HIV replication in vivo. AIDS. 1997;11: 849-857.
98. van der Ende ME, Schutten M, Raschdorff B, et al. CD4 T cells remain the major source of HIV-1 during end stage disease. AIDS. 1999;13:1015-1019.
99. Veazey RS, DeMaria M, Chalifoux LV, et al. Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science. 1998;280:427-431.
100. Calabro ML, Zanotto C, Calderazzo F, et al. HIV-1 infection of the thymus: evidence for a cytopathic and thymotropic viral variant in vivo. AIDS Res Hum Retroviruses. 1995;11:11-19.
101. Kitchen SG, Zack JA. CXCR4 expression during lymphopoiesis: implications for human immunodeficiency virus type 1 infection of the thymus. J Virol. 1997;71:6928-6934.
102. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 1995;373:123-126.
103. Wei X, Ghosh SK, Taylor ME, et al. Viral dynamics in human immu nodeficiency virus type 1 infection. Nature. 1995;373:117-122.
104. Pitcher CJ, Quittner C, Peterson DM, et al. HIV-1-specific CD4+T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression. Nat Med. 1999;5: 518-525.
105. Philpott SM. HIV-1 coreceptor usage, transmission, and disease progression. Curr HIV Res. 2003;1:217-227.
106. Chomont N, El-Far M, Ancuta P, et al. HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat Med. 2009;15:893-900.
107. Brennan TP, Woods JO, Sedaghat AR, Siliciano JD, Siliciano RF, Wilke CO. Analysis of human immunodeficiency virus type 1 viremia and provirus in resting CD4+ T cells reveals a novel source of residual viremia in patients on antiretroviral therapy. J Virol. 2009;83:8470-8481.
108. Mercure L, Phaneuf D, Wainberg MA. Detection of unintegrated human immunodeficiency virus type 1 DNA in persistently infected CD8+ cells. J Gen Virol. 1993;74 (Pt 10):2077-2083.
109. Semenzato G, Agostini C, Ometto L, et al. CD8+ T lymphocytes in the lung of acquired immunodeficiency syndrome patients harbor human immunodeficiency virus type 1. Blood. 1995;85:2308-2314.
110. Brooks DG, Kitchen SG, Kitchen CM, Scripture-Adams DD, Zack JA. Generation of HIV latency during thymopoiesis. Nat Med. 2001;7:459-464.
111. McBreen S, Imlach S, Shirafuji T, et al. Infection of the CD45RA+ (naive) subset of peripheral CD8+ lymphocytes by human immunodeficiency virus type 1 in vivo. J Virol. 2001;75:4091-4102.
112. Flamand L, Crowley RW, Lusso P, Colombini-Hatch S, Margolis DM, Gallo RC. Activation of CD8+ T lymphocytes through the T cell receptor turns on CD4 gene expression: implications for HIV pathogenesis. Proc Natl Acad Sci U S A. 1998;95:3111-3116.
113. Imlach S, McBreen S, Shirafuji T, Leen C, Bell JE, Simmonds P.Activated peripheral CD8 lymphocytes express CD4 in vivo and aretargets for infection by human immunodeficiency virus type 1. J Virol.2001;75:11555-11564.
114. Kitchen SG, Jones NR, LaForge S, et al. CD4 on CD8(+) T cellsdirectly enhances effector function and is a target for HIV infection. Proc Natl Acad Sci U S A. 2004;101:8727-8732.
115. Saha K, Zhang J, Gupta A, Dave R, Yimen M, Zerhouni B. Isolationof primary HIV-1 that target CD8+ T lymphocytes using CD8 as areceptor. Nat Med. 2001;7:65-72.
116. Livingstone WJ, Moore M, Innes D, Bell JE, Simmonds P. Frequentinfection of peripheral blood CD8-positive T-lymphocytes withHIV-1. Edinburgh Heterosexual Transmission Study Group. Lancet.1996;348:649-654.
117. Herbein G, Mahlknecht U, Batliwalla F, et al. Apoptosis of CD8+T cells is mediated by macrophages through interaction of HIV gp120with chemokine receptor CXCR4. Nature. 1998;395:189-194.
118. Kalams SA, Walker BD. The critical need for CD4 help in main-taining effective cytotoxic T lymphocyte responses. J Exp Med.1998;188:2199-2204.
119. Roederer M, Dubs JG, Anderson MT, Raju PA, Herzenberg LA,Herzenberg LA. CD8 naive T cell counts decrease progressively inHIV-infected adults. J Clin Invest. 1995;95:2061-2066.
120. Bohler T, Walcher J, Holzl-Wenig G, et al. Early effects of antiretroviralcombination therapy on activation, apoptosis and regeneration of Tcells in HIV-1-infected children and adolescents. AIDS. 1999;13:779-789.
121. Collman R, Godfrey B, Cutilli J, et al. Macrophage-tropic strainsof human immunodeficiency virus type 1 utilize the CD4 receptor. J Virol. 1990;64:4468-4476.
122. Orenstein JM, Fox C, Wahl SM. Macrophages as a source of HIVduring opportunistic infections. Science. 1997;276:1857-1861.
123. Wahl SM OJ, Smith PD. Macrophage function in HIV infection.Immunology of HIV Infection. New York, NY: New York Plenum;1996:303-336.
124. Crowe SM, Mills J, Kirihara J, Boothman J, Marshall JA, McGrathMS. Full-length recombinant CD4 and recombinant gp120 inhibitfusion between HIV infected macrophages and uninfected CD4-expressing T-lymphoblastoid cells. AIDS Res Hum Retroviruses.1990;6:1031-1037.
125. Meltzer MS, Nakamura M, Hansen BD, Turpin JA, Kalter DC,Gendelman HE. Macrophages as susceptible targets for HIV infection,persistent viral reservoirs in tissue, and key immunoregulatory cellsthat control levels of virus replication and extent of disease. AIDS ResHum Retroviruses. 1990;6:967-971.
126. Deng H, Liu R, Ellmeier W, et al. Identification of a major co-receptorfor primary isolates of HIV-1. Nature. 1996;381:661-666.
127. Doms RW. Chemokine receptors and HIV entry. AIDS. 2001;15 Suppl 1: S34-35.
128. Yi Y, Rana S, Turner JD, Gaddis N, Collman RG. CXCR-4 is expressedby primary macrophages and supports CCR5-independent infectionby dual-tropic but not T-tropic isolates of human immunodeficiencyvirus type 1. J Virol. 1998;72:772-777.
129. Chowdhury IH, Bentsman G, Choe W, Potash MJ, Volsky DJ. Themacrophage response to HIV-1: Intracellular control of X4 virusreplication accompanied by activation of chemokine and cytokinesynthesis. J Neurovirol. 2002;8:599-610.
130. Vadiveloo PK. Macrophages- proliferation, activation, and cell cycleproteins. J Leukoc Biol. 1999;66:579-582.
131. Garaci E, Caroleo MC, Aloe L, et al. Nerve growth factor is anautocrine factor essential for the survival of macrophages infectedwith HIV. Proc Natl Acad Sci U S A. 1999;96:14013-14018.
132. Aquaro S, Bagnarelli P, Guenci T, et al. Long-term survival and virusproduction in human primary macrophages infected by human immu-nodeficiency virus. J Med Virol. 2002;68:479-488.
133. Kohler JJ, Tuttle DL, Coberley CR, Sleasman JW, Goodenow MM.Human immunodeficiency virus type 1 (HIV-1) induces activation ofmultiple STATs in CD4+ cells of lymphocyte or monocyte/macrophagelineages. J Leukoc Biol. 2003;73:407-416.
134. Pelchen-Matthews A, da Silva RP, Bijlmakers MJ, Signoret N, Gor-don S, Marsh M. Lack of p56lck expression correlates with CD4endocytosis in primary lymphoid and myeloid cells. Eur J Immunol.1998;28:3639-3647.
135. O'Brien WA, Namazi A, Kalhor H, Mao SH, Zack JA, Chen IS.Kinetics of human immunodeficiency virus type 1 reverse transcriptionin blood mononuclear phagocytes are slowed by limitations ofnucleotide precursors. J Virol. 1994;68:1258-1263.
136. Heinzinger NK, Bukinsky MI, Haggerty SA, et al. The Vpr protein ofhuman immunodeficiency virus type 1 influences nuclear localizationof viral nucleic acids in nondividing host cells. Proc Natl Acad SciU S A. 1994;91:7311-7315.
137. Tuttle DL, Anders CB, Aquino-De Jesus MJ, et al. Increased replicationof non-syncytium-inducing HIV type 1 isolates in monocyte-derivedmacrophages is linked to advanced disease in infected children. AIDSRes Hum Retroviruses. 2002;18:353-362.
138. Perelson AS, Essunger P, Cao Y, et al. Decay characteristics ofHIV-1-infected compartments during combination therapy. Nature.1997;387:188-191.
139. Embretson J, Zupancic M, Ribas JL, et al. Massive covert infection ofhelper T lymphocytes and macrophages by HIV during the incubationperiod of AIDS. Nature. 1993;362:359-362.
140. McElrath MJ, Steinman RM, Cohn ZA. Latent HIV-1 infection inenriched populations of blood monocytes and T cells from seropositivepatients. J Clin Invest. 1991;87:27-30.
141. Innocenti P, Ottmann M, Morand P, Leclercq P, Seigneurin JM. HIV-1in blood monocytes: frequency of detection of proviral DNA using PCRand comparison with the total CD4 count. AIDS Res Hum Retroviruses.1992;8:261-268.
142. Patterson BK, Till M, Otto P, et al. Detection of HIV-1 DNA andmessenger RNA in individual cells by PCR-driven in situ hybridizationand flow cytometry. Science. 1993;260:976-979.
143. Sonza S, Maerz A, Deacon N, Meanger J, Mills J, Crowe S. Humanimmunodeficiency virus type 1 replication is blocked prior to reversetranscription and integration in freshly isolated peripheral bloodmonocytes. J Virol. 1996;70:3863-3869.
144. Lambotte O, Taoufik Y, de Goer MG, Wallon C, Goujard C, Delfraissy JF.Detection of infectious HIV in circulating monocytes from patients onprolonged highly active antiretroviral therapy. J Acquir Immune DeficSyndr. 2000;23:114-119.
145. Zhu T, Muthui D, Holte S, et al. Evidence for human immunodeficiencyvirus type 1 replication in vivo in CD14(+) monocytes and its potentialrole as a source of virus in patients on highly active antiretroviraltherapy. J Virol. 2002;76:707-716.
146. Sonza S, Mutimer HP, Oelrichs R, et al. Monocytes harbour replication-competent, non-latent HIV-1 in patients on highly active antiretroviraltherapy. AIDS. 2001;15:17-22.
147. Ziegler-Heitbrock HW, Ulevitch RJ. CD14: cell surface receptor anddifferentiation marker. Immunol Today. 1993;14:121-125.
148. Persidsky Y, Ghorpade A, Rasmussen J, et al. Microglial and astrocytechemokines regulate monocyte migration through the blood-brainbarrier in human immunodeficiency virus-1 encephalitis. Am J Pathol.1999;155:1599-1611.
149. Katz SI, Tamaki K, Sachs DH. Epidermal Langerhans cells are derivedfrom cells originating in bone marrow. Nature. 1979;282:324-326.
150. Garrett WS, Chen LM, Kroschewski R, et al. Developmental controlof endocytosis in dendritic cells by Cdc42. Cell. 2000;102:325-334.
151. Tschachler E, Groh V, Popovic M, et al. Epidermal Langerhanscells- a target for HTLV-III/LAV infection. J Invest Dermatol.1987;88:233-237.
152. Geijtenbeek TB, Kwon DS, Torensma R, et al. DC-SIGN, a dendriticcell-specific HIV-1-binding protein that enhances trans-infection ofT cells. Cell. 2000;100:587-597.
153. Turville SG, Cameron PU, Handley A, et al. Diversity of receptors bindingHIV on dendritic cell subsets. Nat Immunol. 2002;3:975-983.
154. Kwon DS, Gregorio G, Bitton N, Hendrickson WA, Littman DR.DC-SIGN-mediated internalization of HIV is required for trans-enhancement of T cell infection. Immunity. 2002;16:135-144.
155. Cameron PU, Freudenthal PS, Barker JM, Gezelter S, Inaba K, Steinman RM. Dendritic cells exposed to human immunodeficiencyvirus type-1 transmit a vigorous cytopathic infection to CD4+ T cells. Science. 1992;257:383-387.
156. Lore K, Sonnerborg A, Brostrom C, et al. Accumulation ofDC-SIGN+CD40+ dendritic cells with reduced CD80 and CD86expression in lymphoid tissue during acute HIV-1 infection. AIDS.2002;16:683-692.
157. Zhang L, Ramratnam B, Tenner-Racz K, et al. Quantifying residualHIV-1 replication in patients receiving combination antiretroviraltherapy. N Engl J Med. 1999;340:1605-1613.
158. Frankel SS, Tenner-Racz K, Racz P, et al. Active replication ofHIV-1 at the lymphoepithelial surface of the tonsil. Am J Pathol.1997;151:89-96.
159. Koopman G, Pals ST. Cellular interactions in the germinal center: roleof adhesion receptors and significance for the pathogenesis of AIDSand malignant lymphoma. Immunol Rev. 1992;126:21-45.
160. Jakubik JJ, Saifuddin M, Takefman DM, Spear GT. Immune complexescontaining human immunodeficiency virus type 1 primary isolates bindto lymphoid tissue B lymphocytes and are infectious for T lymphocytes. J Virol. 2000;74:552-555.
161. Moir S, Malaspina A, Li Y, et al. B cells of HIV-1-infectedpatients bind virions through CD21-complement interactions andtransmit infectious virus to activated T cells. J Exp Med. 2000;192:637-646.
162. Malaspina A, Moir S, Nickle DC, et al. Human immunodeficiencyvirus type 1 bound to B cells: relationship to virus replicat-ing in CD4+ T cells and circulating in plasma. J Virol. 2002;76:8855-8863.
163. Scott-Algara D, Paul P. NK cells and HIV infection: lessons from otherviruses. Curr Mol Med. 2002;2:757-768.
164. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human naturalkiller-cell subsets. Trends Immunol. 2001;22:633-640.
165. Valentin A, Rosati M, Patenaude DJ, et al. Persistent HIV-1 infectionof natural killer cells in patients receiving highly active antiretroviraltherapy. Proc Natl Acad Sci U S A. 2002;99:7015-7020.
166. Lucia MB, Froio N, Tacconelli E, et al. CD16+CD56+CD8+ naturalkiller (NK) cells are decreased during HIV infection. Eur J Histochem.1997;41 Suppl 2: 197-198.
167. Chang J, Jozwiak R, Wang B, et al. Unique HIV type 1 V3 regionsequences derived from six different regions of brain: region-specificevolution within host-determined quasispecies. AIDS Res Hum Retroviruses. 1998;14:25-30.
168. Saksena NK, Wang B, Ge YC, et al. Region-specific changes,gene duplications, and random deletions in the nef gene from HIVtype 1-infected brain tissues and blood of a demented patient. AIDSRes Hum Retroviruses. 1997;13:111-116.
169. Tashima KT, Flanigan TP, Kurpewski J, Melanson SM, Skolnik PR.Discordant Human Immunodeficiency Virus Type 1 drug resistancemutations, including K103N, observed in cerebrospinal fluid andplasma. Clin Infect Dis. 2002;35:82-83.
170. Kim AE, Dintaman JM, Waddell DS, Silverman JA. Saquinavir, anHIV protease inhibitor, is transported by P-glycoprotein. J PharmacolExp Ther. 1998;286:1439-1445.
171. Kim RB, Fromm MF, Wandel C, et al. The drug transporterP-glycoprotein limits oral absorption and brain entry of HIV-1 proteaseinhibitors. J Clin Invest. 1998;101:289-294.
172. Gottesman MM, Pastan I. Biochemistry of multidrug resistancemediated by the multidrug transporter. Annu Rev Biochem.1993;62:385-427.
173. Choo EF, Leake B, Wandel C, et al. Pharmacological inhibition ofP-glycoprotein transport enhances the distribution of HIV-1 prote-ase inhibitors into brain and testes. Drug Metab Dispos. 2000;28:655-660.
174. Smit TK, Brew BJ, Tourtellotte W, Morgello S, Gelman BB, Saksena NK. Independent evolution of human immunodeficiency virus (HIV) drugresistance mutations in diverse areas of the brain in HIV-infectedpatients, with and without dementia, on antiretroviral treatment. J Virol. 2004;78:10133-10148.
175. Brew BJ, Rosenblum M, Cronin K, Price RW. AIDS dementia complexand HIV-1 brain infection: clinical-virological correlations. AnnNeurol. 1995;38:563-570.
176. Dejucq N, Jegou B. Viruses in the mammalian male genital tract andtheir effects on the reproductive system. Microbiol Mol Biol Rev.2001;65:208-231.
177. Cohen MS, Hoffman IF, Royce RA, et al. Reduction of concentrationof HIV-1 in semen after treatment of urethritis: implications for pre-vention of sexual transmission of HIV-1. AIDSCAP Malawi ResearchGroup. Lancet. 1997;349:1868-1873.
178. Bart J, Groen HJ, van der Graaf WT, et al. An oncological view on theblood-testis barrier. Lancet Oncol. 2002;3:357-363.
179. Byrn RA, Zhang D, Eyre R, McGowan K, Kiessling AA. HIV-1 insemen: an isolated virus reservoir. Lancet. 1997;350:1141.
180. Ghosn J, Viard JP, Katlama C, et al. Evidence of genotypic resistancediversity of archived and circulating viral strains in blood and semenof pre-treated HIV-infected men. AIDS. 2004;18:447-457.
181. Kemal KS, Foley B, Burger H, et al. HIV-1 in genital tract and plasma ofwomen: compartmentalization of viral sequences, coreceptor usage, andglycosylation. Proc Natl Acad Sci U S A. 2003;100:12972-12977.
182. Poss M, Rodrigo AG, Gosink JJ, et al. Evolution of envelope sequencesfrom the genital tract and peripheral blood of women infected with cladeA human immunodeficiency virus type 1. J Virol. 1998;72:8240-8251.
183. Zhang L, Rowe L, He T, et al. Compartmentalization of surfaceenvelope glycoprotein of human immunodeficiency virus type 1 duringacute and chronic infection. J Virol. 2002;76:9465-9473.
184. Barnett SW, Barboza A, Wilcox CM, Forsmark CE, Levy JA.Characterization of human immunodeficiency virus type 1 strainsrecovered from the bowel of infected individuals. Virology.1991;182:802-809.
185. al-Mulla W, Church D, Gill MJ. Phenotypic variations and switches inHIV isolated from the blood and the gastrointestinal tissues of patientswith HIV-1 infection. HIV/GI Research Study Group. J Med Virol.1997;52:31-34.
186. van der Hoek L, Sol CJ, Maas J, Lukashov VV, Kuiken CL, Goud-smit J. Genetic differences between human immunodeficiency virustype 1 subpopulations in faeces and serum. J Gen Virol. 1998;79(Pt 2):259-267.
187. Poles MA, Elliott J, Vingerhoets J, et al. Despite high concordance,distinct mutational and phenotypic drug resistance profiles in humanimmunodeficiency virus type 1 RNA are observed in gastrointestinalmucosal biopsy specimens and peripheral blood mononuclear cellscompared with plasma. J Infect Dis. 2001;183:143-148.
188. Simmonds P, Zhang LQ, McOmish F, Balfe P, Ludlam CA, Brown AJ.Discontinuous sequence change of human immunodeficiency virus(HIV) type 1 env sequences in plasma viral and lymphocyte-associ-ated proviral populations in vivo: implications for models of HIVpathogenesis. J Virol. 1991;65:6266-6276.
189. Wang YM, Dyer WB, Workman C, Wang B, Sullivan JS, Saksena NK.Molecular evidence for drug-induced compartmentalization of HIV-1quasispecies in a patient with periodic changes to HAART. AIDS.2000;14:2265-2272.
190. Romano L, Venturi G, Catucci M, De Milito A, Valensin PE, Zazzi M. Evaluation of cell-free and cell-associated peripheral blood humanimmunodeficiency virus type 1 RNA response to antiretroviral therapy. J Infect Dis. 1999;179:361-366.
191. Chun TW, Stuyver L, Mizell SB, et al. Presence of an inducible HIV-1latent reservoir during highly active antiretroviral therapy. Proc NatlAcad Sci U S A. 1997;94:13193-13197.
192. Finzi D, Hermankova M, Pierson T, et al. Identification of a reservoirfor HIV-1 in patients on highly active antiretroviral therapy. Science.1997;278:1295-1300.
193. Pierson T, Hoffman TL, Blankson J, et al. Characterization of chemokinereceptor utilization of viruses in the latent reservoir for human immu-nodeficiency virus type 1. J Virol. 2000;74:7824-7833.
194. Gunthard HF, Frost SD, Leigh-Brown AJ, et al. Evolution of envelopesequences of human immunodeficiency virus type 1 in cellular reservoirsin the setting of potent antiviral therapy. J Virol. 1999;73:9404-9412.
195. Aquaro S, Calio R, Balestra E, et al. Clinical implications of HIVdynamics and drug resistance in macrophages. J Biol Regul HomeostAgents. 1998;12:23-27.
196. Venturi G, Romano L, Carli T, et al. Divergent distribution of HIV-1drug-resistant variants on and off antiretroviral therapy. Antivir Ther.2002;7:245-250.
197. Kepler TB, Perelson AS. Drug concentration heterogeneityfacilitates the evolution of drug resistance. Proc Natl Acad Sci U S A.1998;95:11514-11519.
198. Turriziani O, Schuetz JD, Focher F, et al. Impaired 2',3'-dideoxy-3'-thiacytidine accumulation in T-lymphoblastoid cells as a mechanism ofacquired resistance independent of multidrug resistant protein 4 witha possible role for ATP-binding cassette C11. Biochem J. 2002;368: 325-332.
199. Saksena NK, Haddad DN. Viral reservoirs an impediment toHAART: new strategies to eliminate HIV-1. Curr Drug Targets InfectDisord. 2003;3:179-206.
200. Lucia MB, Rutella S, Golotta C, Leone G, Cauda R. Differentialinduction of P-glycoprotein and MRP by rifamycins in T lympho-cytes from HIV-1/tuberculosis co-infected patients. AIDS. 2002;16:1563-1565.
201. Kulkosky J, Culnan DM, Roman J, et al. Prostratin: activation of latentHIV-1 expression suggests a potential inductive adjuvant therapy forHAART. Blood. 2001;98:3006-3015.
202. Lehrman G, Hogue IB, Palmer S, et al. Depletion of latentHIV-1 infection in vivo: a proof-of-concept study. Lancet. 2005;366:549-555.
203. Savarino A, Mai A, Norelli S, et al. "Shock and kill" effects of classI-selective histone deacetylase inhibitors in combination with theglutathione synthesis inhibitor buthionine sulfoximine in cell linemodels for HIV-1 quiescence. Retrovirology. 2009;6:52.
204. Ylisastigui L, Archin NM, Lehrman G, Bosch RJ, Margolis DM.Coaxing HIV-1 from resting CD4 T cells: histone deacetylaseinhibition allows latent viral expression. AIDS. 2004;18:1101-1108.
205. Brooks DG, Hamer DH, Arlen PA, et al. Molecular characteriza-tion, reactivation, and depletion of latent HIV. Immunity. 2003;19:413-423.
206. Marsden MD, Xu J, Hamer D, Zack JA. Short communication:Activating stimuli enhance immunotoxin-mediated killing ofHIV-infected macrophages. AIDS Res Hum Retroviruses. 2008;24:1399-1404.
207. Turner LS, Tsygankov AY, Henderson EE. StpC-based genetherapy targeting latent reservoirs of HIV-1. Antiviral Res. 2006;72: 233-241.